Edit
Specific Diagnostics
https://www.specificdx.com/Last activity: 05.04.2022
Probably Closed - Reference to BioMerieux SA
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific’s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution.
Specific’s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific’s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections.
Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.
Specific is located in Mountain View, California.
For more information, visit www.specificdx.com.
Corporate Contact, email: press@specificdx.com
Specific’s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific’s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections.
Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.
Specific is located in Mountain View, California.
For more information, visit www.specificdx.com.
Corporate Contact, email: press@specificdx.com
Location: United States, California, Mountain View
Employees: 51-200
Phone: +91 98743 07415
Total raised: $15.4M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Telegraph ... | thpartners... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.06.2020 | - | $2.9M | - |
| 06.09.2019 | - | $12.5M | - |
Mentions in press and media 6
| Date | Title | Description |
| 05.04.2022 | Specific Diagnostics Invited to Present at the William Blair & Company Annual Growth Stock Conference | SPECIFIC REVEAL® Rapid AST System “We anticipate and look forward to a productive exchange of information with leading investors as we bring Reveal to the market in Europe alongside our distribution partner bioMérieux, and as we complete ou... |
| 14.02.2022 | Specific Diagnostics Invited to Present at the BTIG Virtual MedTech, Digital Health, Life Science Tools and Diagnostics Investor Conference | Specific Reveal® Rapid AST System “We are pleased to share our story with public company investors as we bring Reveal to the market in Europe along with our distribution partner bioMérieux, and now directly in the United States.” said Dr. R... |
| 29.06.2021 | bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe | “Every lab we encounter wants rapid, easy-to-use susceptibility testing at the right price; we couldn’t reach them all without partnering with an organization with the scale and quality of bioMérieux,” said Paul A. Rhodes, Ph.D., CEO of Spe... |
| 02.06.2020 | Specific Diagnostics Announces that NIAID has Awarded the Company a Further $2.9 million for the Commercial Development of the Reveal Rapid Antibiotic Susceptibility Testing (AST) System | MOUNTAIN VIEW, California, June 2, 2020 – Specific Diagnostics today announces that the National Institute for Allergy and Infectious Disease (NIAID) has awarded a second major grant to drive the commercial introduction of Specific’s Reveal... |
| 06.09.2019 | Specific Diagnostics Receives $12.5M Investment | MOUNTAIN VIEW, CA, Specific Diagnostics today announced an investment of $12.5M by Telegraph Hill Partners. >> Click here for more funding data on Specific Diagnostics >> To export Specific Diagnostics funding data to PDF an... |
| 06.09.2019 | Specific Diagnostics Receives Investment from Telegraph Hill Partners | Specific Diagnostics, a Mountain View, CA-based developer of in vitro diagnostic systems for the detection and identification of microorganisms while they grow in culture, received $12.5M investment from Telegraph Hill Partners. In conjunct... |